249 related articles for article (PubMed ID: 28635741)
1. [A place of first-line drugs in treatment of multiple sclerosis].
Kasatkin DS
Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(12):145-151. PubMed ID: 28635741
[TBL] [Abstract][Full Text] [Related]
2. Five-year outcome in the copaxone observatory: a nationwide cohort of patients with multiple sclerosis starting treatment with glatiramer acetate in France.
Lebrun-Frenay C; Moulignier A; Pierrot-Deseilligny C; Benrabah R; Moreau T; Lubetzki C; Monchecourt F;
J Neurol; 2019 Apr; 266(4):888-901. PubMed ID: 30730008
[TBL] [Abstract][Full Text] [Related]
3. Glatiramer acetate during early pregnancy: A prospective cohort study.
Herbstritt S; Langer-Gould A; Rockhoff M; Haghikia A; Queisser-Wahrendorf A; Gold R; Hellwig K
Mult Scler; 2016 May; 22(6):810-6. PubMed ID: 26754804
[TBL] [Abstract][Full Text] [Related]
4. [Efficacy, safety and tolerability of glatiramer acetate injections in dose 40 mg/ml in patients with relapsing-remitting multiple sclerosis].
Boyko AN; Alifirova VM
Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(11):135-139. PubMed ID: 29265099
[TBL] [Abstract][Full Text] [Related]
5. Multiple sclerosis. Generic glatiramer acetate--a step toward cheaper MS drugs?
Sørensen PS
Nat Rev Neurol; 2016 Jan; 12(1):5-6. PubMed ID: 26635211
[TBL] [Abstract][Full Text] [Related]
6. Equivalence of Generic Glatiramer Acetate in Multiple Sclerosis: A Randomized Clinical Trial.
Cohen J; Belova A; Selmaj K; Wolf C; Sormani MP; Oberyé J; van den Tweel E; Mulder R; Koper N; Voortman G; Barkhof F;
JAMA Neurol; 2015 Dec; 72(12):1433-41. PubMed ID: 26458034
[TBL] [Abstract][Full Text] [Related]
7. Differential glatiramer acetate treatment persistence in treatment-naive patients compared to patients previously treated with interferon.
Fernández-Fournier M; Tallón-Barranco A; Chamorro B; Martínez-Sánchez P; Puertas I
BMC Neurol; 2015 Aug; 15():141. PubMed ID: 26286576
[TBL] [Abstract][Full Text] [Related]
8. Development of Glatopa® (Glatiramer Acetate): The First FDA-Approved Generic Disease-Modifying Therapy for Relapsing Forms of Multiple Sclerosis.
Bell C; Anderson J; Ganguly T; Prescott J; Capila I; Lansing JC; Sachleben R; Iyer M; Fier I; Roach J; Storey K; Miller P; Hall S; Kantor D; Greenberg BM; Nair K; Glajch J
J Pharm Pract; 2018 Oct; 31(5):481-488. PubMed ID: 28847230
[TBL] [Abstract][Full Text] [Related]
9. [Comparative, placebo-controlled clinical study of efficacy and safety of glatiramer acetate 20 mg in patients with relapsing-remitting multiple sclerosis: results of the first year of the study].
Boyko AN; Lashch NY; Sharanova SN; Zakharova MN; Trifonova OV; Simaniv TO; Lysogorskaya EV; Guryanova OE; Kotov SV; Iakushina TI; Lizhdvoy VY; Belova YA; Khabirov FA; Babicheva NN; Khaibullin TI; Granatov EV; Averyanova LA; Sazonov DV; Odinak MM; Trinitatsky YV; Tsukurova LA; Sergeeva AI; Ivanov RA; Shustova MS
Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(10 Pt 2):61-67. PubMed ID: 28139613
[TBL] [Abstract][Full Text] [Related]
10. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group.
Johnson KP; Brooks BR; Cohen JA; Ford CC; Goldstein J; Lisak RP; Myers LW; Panitch HS; Rose JW; Schiffer RB; Vollmer T; Weiner LP; Wolinsky JS
Neurology; 1998 Mar; 50(3):701-8. PubMed ID: 9521260
[TBL] [Abstract][Full Text] [Related]
11. Risk-benefit assessment of glatiramer acetate in multiple sclerosis.
Ziemssen T; Neuhaus O; Hohlfeld R
Drug Saf; 2001; 24(13):979-90. PubMed ID: 11735654
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of a three-times-weekly dosing regimen of glatiramer acetate in relapsing-remitting multiple sclerosis patients: 3-year results of the Glatiramer Acetate Low-Frequency Administration open-label extension study.
Khan O; Rieckmann P; Boyko A; Selmaj K; Ashtamker N; Davis MD; Kolodny S; Zivadinov R
Mult Scler; 2017 May; 23(6):818-829. PubMed ID: 27503905
[TBL] [Abstract][Full Text] [Related]
13. Two decades of glatiramer acetate: From initial discovery to the current development of generics.
Weinstock-Guttman B; Nair KV; Glajch JL; Ganguly TC; Kantor D
J Neurol Sci; 2017 May; 376():255-259. PubMed ID: 28431621
[TBL] [Abstract][Full Text] [Related]
14. Eighteen-month safety analysis of offspring breastfed by mothers receiving glatiramer acetate therapy for relapsing multiple sclerosis - COBRA study.
Ciplea AI; Kurzeja A; Thiel S; Haben S; Alexander J; Adamus E; Hellwig K
Mult Scler; 2022 Sep; 28(10):1641-1650. PubMed ID: 35362346
[TBL] [Abstract][Full Text] [Related]
15. Fatigue Improvement after Switching Multiple Sclerosis Treatment from Interferon-β to Glatiramer Acetate in Clinical Practice.
Meca-Lallana J; Hernández L; Caminero AB; Girón JM; Cano-Orgaz A; Carcelén-Gadea M; Muñoz D; Durán-Ferreras E; Martín-Hernández J; Sánchez-de la Rosa R;
Eur Neurol; 2016; 76(1-2):40-7. PubMed ID: 27376845
[TBL] [Abstract][Full Text] [Related]
16. Glatiramer acetate (Copaxone) therapy for multiple sclerosis.
Dhib-Jalbut S
Pharmacol Ther; 2003 May; 98(2):245-55. PubMed ID: 12725872
[TBL] [Abstract][Full Text] [Related]
17. Recurrent Nicolau syndrome associated with subcutaneous glatiramer acetate injection--a case report.
Zecca C; Mainetti C; Blum R; Gobbi C
BMC Neurol; 2015 Dec; 15():249. PubMed ID: 26630967
[TBL] [Abstract][Full Text] [Related]
18. Safety evaluations of offspring breastfed by mothers receiving glatiramer acetate for relapsing multiple sclerosis.
Ciplea AI; Kurzeja A; Thiel S; Haben S; Adamus E; Hellwig K
Mult Scler Relat Disord; 2023 Jul; 75():104771. PubMed ID: 37245349
[TBL] [Abstract][Full Text] [Related]
19. [The resolution of the expert body for the section on demyelinating diseases of the Russian Society of Neurologists and Russian Executive Committee of multiple sclerosis researchers (Kazan, 19 november 2015) on the 'Current principles and optimization of treatment of patients with relapsing-remitting multiple sclerosis with glatiramer acetate'].
Redaktsiia
Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(2 Pt 2):78-79. PubMed ID: 28635770
[No Abstract] [Full Text] [Related]
20. [Long-term effects of glatiramer acetate in multiple sclerosis].
Brochet B
Rev Neurol (Paris); 2008 Nov; 164(11):917-26. PubMed ID: 18790510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
